Henan Genuine Biotech

Privately held: no public share price

Assets

(4 total)
4Total Assets
0Approved
1Phase 3 / Filed
3Phase 1–2 / Early
3Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Phase 3
HIV reverse transcriptaseSmall molecule
HIVCOVID-19
Phase 2
HIV reverse transcriptaseSmall molecule
HIV
Phase 1/2
EGFRSmall molecule
Non-Small Cell Lung Cancer
Phase 1/2
Undisclosed / early pipelineSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
CL-197Phase 2HIV-1 Infection
Est. primary completion 2026-12 · NCT07308782 · CT.gov ↗
What to watch
2027 (2)
July 2027 (1)
Dositinib mesylate + GEN-725Phase 1/2Non-Small Cell Lung Cancer
Est. primary completion 2027-07-31 · NCT07362940 · CT.gov ↗
What to watch
December 2027 (1)
Dositinib mesylatePhase 1/2Non-Small Cell Lung Cancer
Est. primary completion 2027-12-31 · NCT07231068 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.